Literature DB >> 1710781

Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor.

L R Bandara1, N B La Thangue.   

Abstract

The transforming proteins of several DNA tumour viruses, including adenovirus E1a and simian virus 40 large T antigen, complex with the retinoblastoma (Rb) tumour-suppressor gene product. This requires regions in these viral proteins necessary for transformation and is thought to inactivate the growth-suppressing properties of the Rb protein by disrupting its interaction with cellular targets. Indeed, regions of Rb required to form a complex with E1a and large T antigen are often mutated in transformed cells. The level at which the Rb protein regulates proliferation is unknown, although one possibility is transcription. We have previously characterized a sequence-specific transcription factor, DRTF1, the activity of which is downregulated as embryonal carcinoma stem cells differentiate. DRTF1 is found in several discrete protein complexes (a, b and c) which are of different sizes but have the same DNA specificity. We now show that one of these also contains the Rb protein and, further, that the adenovirus E1a protein causes the dissociation of the Rb protein from this complex. This requires conserved regions 1 and 2 of E1a that are known to be required for efficient transformation. These results demonstrate that the Rb protein forms a complex with a DNA-bound transcription factor, and suggests that the Rb protein might act by regulating transcription.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710781     DOI: 10.1038/351494a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  150 in total

1.  Induction of AP-1 DNA-binding activity and c-fos mRNA by the adenovirus 243R E1A protein and cyclic AMP requires domains necessary for transformation.

Authors:  R W Gedrich; S T Bayley; D A Engel
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins.

Authors:  N Dyson; P Guida; K Münger; E Harlow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene.

Authors:  P A Hamel; R M Gill; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

4.  Identification of a 60-kilodalton Rb-binding protein, RBP60, that allows the Rb-E2F complex to bind DNA.

Authors:  S K Ray; M Arroyo; S Bagchi; P Raychaudhuri
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

5.  Promoter-specific trans-activation by the adenovirus E1A12S product involves separate E1A domains.

Authors:  V B Kraus; E Moran; J R Nevins
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

Review 6.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

7.  Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein.

Authors:  W C Phelps; K Münger; C L Yee; J A Barnes; P M Howley
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.

Authors:  M Xu; K A Sheppard; C Y Peng; A S Yee; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site.

Authors:  A Schulze; K Zerfass; D Spitkovsky; S Middendorp; J Bergès; K Helin; P Jansen-Dürr; B Henglein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Transcriptional repression by the Rb-related protein p107.

Authors:  M Zamanian; N B La Thangue
Journal:  Mol Biol Cell       Date:  1993-04       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.